Skip to main content
Clinical Trials/NCT01884974
NCT01884974
Unknown
Not Applicable

A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.

Carmel Medical Center1 site in 1 country150 target enrollmentJuly 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Myeloproliferative Disease
Sponsor
Carmel Medical Center
Enrollment
150
Locations
1
Primary Endpoint
pulmonary hypertension
Last Updated
10 years ago

Overview

Brief Summary

Pulmonary hypertension (PH) is defined as a group of diseases characterised by an elevated mean pulmonary artery pressure (Ppa) ≥25 mmHg at rest. Recently, chronic myeloproliferative diseases (CMPD) associated with pulmonary hypertension were included in the group 5 category, corresponding to PH for which the aetiology is unclear and/or multifactorial. CMPD include chronic myelogenous leukaemia, chronic neutrophilic leukaemia and chronic eosinophilic leukaemia (which primarily express a myeloid phenotype and polycythaemia vera), idiopathic myelofibrosis, and essential thrombocytosis in which erythroid or megakaryocytic hyperplasia predominates.

The purpose of this research:

  1. Assess Prevalence of PH in patients with CMPD in Northern Israel
  2. Describe the demographics and clinical course in patients with CMPD who are diagnosed with PH.

Detailed Description

study will include the following: * sex * age * BMI * ethnicity * age diagnosed with Myeloproliferative disease * clinical manifestations of the myeloproliferative disease * JAK2 mutation * known hematological complications

Registry
clinicaltrials.gov
Start Date
July 2013
End Date
June 2016
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Carmel Medical Center
Responsible Party
Principal Investigator
Principal Investigator

Shoshan Perek

Dr Shoshan Perek

Carmel Medical Center

Eligibility Criteria

Inclusion Criteria

  • consenting patients diagnosed with a myeloproliferative disease

Exclusion Criteria

  • Refusal to have an echocardiogram or answer the St. George respiratory questionnaire

Outcomes

Primary Outcomes

pulmonary hypertension

Time Frame: 1 year

all patients with myeloproliferative diseases in the study will be evaluated by an echocardiogram. Pulmonary hypertension will be considered when the average pulmonary arterial pressure is equal or above 25 mmHg.

Secondary Outcomes

  • St George Respiratory Questionnaire(1 year)

Study Sites (1)

Loading locations...

Similar Trials